MedTrace Logo

Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy

NCT02432365 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2017-10-30

No results posted yet for this study

Summary

The purpose was to establish a quick (7-day) cycle schedule of paclitaxel (60 mg/m2) combining with cisplatin (40 mg/m2) NAC regimen could be tolerated without interfering the following surgical treatment and a favorable overall survival rate for stages IB2 and IIA2 cervical squamous cell carcinoma (SCC).

Conditions

Interventions

DRUG

paclitaxel

7-day cycle schedule of paclitaxel (60 mg/m2)

DRUG

cisplatin

7-day cycle schedule of cisplatin (40 mg/m2)

PROCEDURE

Radical hysterectomy and bilateral pelvic lymphadenectomy

2 weeks after last course of neoadjuvant chemotherapy

Sponsors & Collaborators

  • Asian Gynecologic Oncology Group

    collaborator OTHER

  • Taiwanese Gynecologic Oncology Group

    collaborator UNKNOWN

  • Chang Gung Memorial Hospital

    lead OTHER

Principal Investigators

  • Huei-Jean Huang, M.D · Gynecologic oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02432365 on ClinicalTrials.gov